Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:KURANASDAQ:MRVINASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.26$1.33$0.95▼$5.17$136.43M0.421.18 million shs404,328 shsKURAKura Oncology$5.64-9.6%$6.30$5.41▼$23.48$488.28M0.51.19 million shs2.68 million shsMRVIMaravai LifeSciences$2.22-3.5%$2.07$1.67▼$11.16$565.35M0.192.35 million shs2.24 million shsSTOKStoke Therapeutics$9.36-1.5%$8.26$5.35▼$17.58$511.03M1.2711,112 shs471,276 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-3.82%+5.88%-43.88%+9.57%KURAKura Oncology-9.62%-6.31%-11.46%-31.60%-74.99%MRVIMaravai LifeSciences-3.48%+5.71%+5.71%-45.99%-79.91%STOKStoke Therapeutics-1.47%-4.10%-1.84%+12.36%-40.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.8743 of 5 stars3.62.00.00.03.51.71.3KURAKura Oncology4.2904 of 5 stars4.52.00.04.72.50.80.6MRVIMaravai LifeSciences3.9769 of 5 stars4.11.00.04.41.60.81.3STOKStoke Therapeutics3.4586 of 5 stars3.60.00.04.82.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$10.00693.65% UpsideKURAKura Oncology 2.93Moderate Buy$24.50334.40% UpsideMRVIMaravai LifeSciences 2.25Hold$6.64199.05% UpsideSTOKStoke Therapeutics 3.29Buy$23.20147.86% UpsideCurrent Analyst Ratings BreakdownLatest ACRS, MRVI, KURA, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/13/2025MRVIMaravai LifeSciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/13/2025MRVIMaravai LifeSciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.004/29/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.004/28/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$17.78M7.67N/AN/A$2.22 per share0.57KURAKura Oncology$67.99M7.18N/AN/A$5.35 per share1.05MRVIMaravai LifeSciences$241.86M2.34$0.05 per share41.71$3.14 per share0.71STOKStoke Therapeutics$190.91M2.68N/AN/A$3.57 per share2.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.39N/AN/AN/A-136.65%-40.26%-31.71%8/6/2025 (Estimated)KURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%N/AMRVIMaravai LifeSciences-$119.03M-$1.14N/AN/AN/A-81.13%-6.61%-3.45%8/6/2025 (Estimated)STOKStoke Therapeutics-$104.70M$0.79N/AN/AN/A-629.90%-54.45%-40.77%8/5/2025 (Estimated)Latest ACRS, MRVI, KURA, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MRVIMaravai LifeSciences-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million2/26/2025Q4 2024KURAKura Oncology-$0.65-$0.22+$0.43-$0.22$57.96 million$53.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A7.037.03KURAKura Oncology0.0211.4711.47MRVIMaravai LifeSciences0.8910.749.94STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%KURAKura OncologyN/AMRVIMaravai LifeSciences50.25%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%KURAKura Oncology6.40%MRVIMaravai LifeSciences0.63%STOKStoke Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million66.86 millionOptionableKURAKura Oncology13086.58 million73.49 millionOptionableMRVIMaravai LifeSciences610254.66 million250.94 millionOptionableSTOKStoke Therapeutics10054.60 million46.98 millionOptionableACRS, MRVI, KURA, and STOK HeadlinesRecent News About These CompaniesDeutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 22 at 3:53 AM | marketbeat.comToronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 21 at 5:58 AM | marketbeat.comTang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)May 20, 2025 | marketbeat.comChardan Capital Has Strong Forecast for STOK FY2025 EarningsMay 20, 2025 | marketbeat.comRTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 18, 2025 | marketbeat.comAnalysts Issue Forecasts for STOK FY2026 EarningsMay 18, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for STOK FY2025 EarningsMay 18, 2025 | americanbankingnews.comWedbush Forecasts Stronger Earnings for Stoke TherapeuticsMay 18, 2025 | americanbankingnews.comQ2 EPS Forecast for Stoke Therapeutics Lowered by AnalystMay 18, 2025 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor FitzgeraldMay 17, 2025 | marketbeat.comHC Wainwright Cuts Stoke Therapeutics (NASDAQ:STOK) Price Target to $35.00May 17, 2025 | americanbankingnews.comWall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a BetMay 16, 2025 | zacks.comMPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 16, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at Cantor FitzgeraldMay 16, 2025 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings BeatMay 15, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Strong EarningsMay 15, 2025 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.60 Consensus PT from BrokeragesMay 14, 2025 | americanbankingnews.comStoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue EstimatesMay 13, 2025 | zacks.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LPMay 13, 2025 | marketbeat.comGranahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 12, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from BrokeragesMay 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRS, MRVI, KURA, and STOK Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.26 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.26 +0.00 (+0.40%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Kura Oncology NASDAQ:KURA$5.64 -0.60 (-9.62%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.70 +0.06 (+1.06%) As of 05/23/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Maravai LifeSciences NASDAQ:MRVI$2.22 -0.08 (-3.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Stoke Therapeutics NASDAQ:STOK$9.36 -0.14 (-1.47%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.30 -0.05 (-0.59%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
